207 results on '"Le Malicot, K."'
Search Results
2. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial
3. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
4. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
5. Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
6. OC-0277 Capecitabine or 5-fluorouracil infusion with radiotherapy of anal cancers in the FFCD-Anabase cohort
7. Sporadic non-functional neuroendocrine pancreatic incidentalomas (NF-NEI) ≤ 2 cm: risk of progression over 3 years. Results of the prospective multicenter French national study IPANEMA
8. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
9. 429P Management of localized anal cancer and prognostic factors in the elderly: Results of the French multicenter cohort FFCD – ANABASE
10. 59P Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
11. 598TiP PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
12. OC-0270 Final results of the French national cohort ANABASE : treatment and outcome in anal cancer
13. MO-0226 Clinical outcomes of HIV-positive patients with anal cancer in the ANABASE multicentric cohort
14. Efficacité et toxicité de la (chimio)radiothérapie chez les patients séropositifs pour le VIH atteints d’un carcinome épidermoïde du canal anal, analyse en sous-groupe de la cohorte multicentrique Anabase
15. 391MO Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients: A pooled analysis of 3 adjuvant trials
16. PH-0113 Anti-Epidermal Growth Factor Receptor Therapy in combination with Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase II Study with Panitumumab (FFCD 0904)
17. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies
18. LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD
19. 651P DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
20. 629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
21. 567P Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
22. Apport de la radiomique sur IRM pour prédire la réponse à 2 ans après chimioradiothérapie des cancers du canal anal localement évolués
23. 444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers
24. 1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
25. 1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial
26. Loss of SMARCB1 expression in colon carcinoma
27. LBA46 Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): The PRODIGE 41-BEVANEC randomized phase II study
28. 1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
29. Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies
30. Dose-response relationship in the context of a maintenance randomized control trial: reanalysis of the PRODIGE 9 trial
31. REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors
32. Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial
33. Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
34. Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8
35. miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial
36. Stratégie permettant la prise en compte d’évènements intercurrents dans l’évaluation d’un essai clinique en oncologie digestive
37. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
38. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
39. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
40. Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
41. Predictive factors for early progression during induction chemotherapy (IC) and chemotherapy-free interval (CFI): Analysis from PRODIGE 9 trial
42. PD-021 - Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies
43. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8)
44. PRODIGE 25 (FFCD 11-01) - Phase II randomized trial evaluating aflibercept associated with LV5FU2 regimen as first line treatment of non-resectable metastatic colorectal cancers (FOLFA)
45. Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial
46. 521P - miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial
47. 476P - Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
48. 60PD - Colon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8
49. 2305 Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part
50. O-009 Prognostic value of BRAFV600E and KRAS exon 2 mutations in microsatellite stable stage III colon cancers from patients treated with FOLFOX + /- cetuximab: A pooled analysis from PETACC8 and N0147 trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.